S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This study will conduct a phase II study of gemcitabine, erlotinib, and S-1 as first-line
chemotherapy in patients with advanced pancreatic cancer and evaluate the EGFR expression,
KRAS mutation, and BRAF mutation as predictive or prognostic markers